Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Extracellular Matrix Proteins » Anti -Tenascin (TN, Tenascin-C, TNC, TN-C, 150-225, Cytotactin, Glioma-associated Extracellular Matrix Antigen, GMEM, GP 150-225, Hexabrachion, HXB, JI, MGC167029, Myotendinous Antigen, Neuronectin)

Anti -Tenascin (TN, Tenascin-C, TNC, TN-C, 150-225, Cytotactin, Glioma-associated
Extracellular Matrix Antigen, GMEM, GP 150-225, Hexabrachion, HXB, JI, MGC167029,
Myotendinous Antigen, Neuronectin)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Monoclonal Mouse Supernatant B IH IF
Tenascin is a large hexameric extracellular matrix molecule with oncofetal properties. During embryonic development the protein is expressed in many parenchymatous organs, where it appears to have a regulating role in epithelial differentiation. In most mature tissues the expression is restricted to the papillary dermis, but reappears in tissue regeneration and repair and in neoplasia. In basal cell carcinoma two forms (Mr 210,000 and 300,000) of tenascin can be found, in contrast to normal skin and fibroblasts, where one form predominantly exists (Mr 300,000).
Catalog #T2550-02B
Tenascins were first characterized in the early 1980ís. Only recently have more elective studies been done. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. The preliminary results of these studies clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. Tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy. Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.
ApplicationsSuitable for use in Immunofluorecence, immunohistochemistry and Western Blot. Other applications not tested.
Recommended DilutionImmunohistochemistry: formalin-fixed and paraffin.
Storage and StabilityMay be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Clone TypeMonoclonal
IsotypeIgG2a
Clone NoDB7
HostMouse
SourceHuman
ConcentrationAs reported
FormSupplied as a liquid in PBS, 1% BSA, 0.1 % sodium azide.
PuritySupernatant
ImmunogenTenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography.
SpecificityRecognizes the Mr 250000 and 180000 human tenascin polypeptides in immunoprecipitation and in immunoblots the Mr 250000 polypeptide. Recognizes the fibrinogen-like knob-domain of tenascin protein.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links